Onset of Relief of Dyspnoea With Budesonide/Formoterol or Salbutamol Following Methacholine-Induced Severe Bronchoconstriction in Adults With Asthma: A Double-Blind, Placebo-Controlled Study

Respiratory Research - United Kingdom
doi 10.1186/1465-9921-7-141
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Inhaled Budesonide for Adults With Mild-To-Moderate Asthma: A Randomized Placebo-Controlled, Double-Blind Clinical Trial

Sao Paulo Medical Journal
Medicine
2001English

Reversion of Methacholine Induced Bronchoconstriction With Inhaled Diazepam in Patients With Asthma

Revista Medica de Chile
Medicine
2016English

Randomised, Double-Blind, Placebo-Controlled Trial of EPs 7630 in Adults With COPD

Respiratory Medicine
PulmonaryRespiratory Medicine
2013English

Jakyakgamcho-Tang in the Relief of Delayed-Onset Muscle Soreness in Healthy Adults: Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Crossover Design Clinical Trial

Trials
MedicinePharmacology
2020English

Visible Light-Induced Healing of Diabetic or Venous Foot Ulcers: A Placebo-Controlled Double-Blind Study

Photomedicine and Laser Surgery
Nuclear MedicineRadiologyBiomedical EngineeringImaging
2011English

A Double-Blind, Placebo-Controlled Study of Risperidone in Adults With Autistic Disorder and Other Pervasive Developmental Disorders

Archives of General Psychiatry
1998English

Different Inhaler Devices in Acute Asthma Attacks: A Randomized, Double-Blind, Placebo-Controlled Study

Jornal de Pediatria
Child HealthPediatricsPerinatology
2005English

Dynamic Hyperinflation and Flow Limitation During Methacholine-Induced Bronchoconstriction in Asthma

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
1999English

Budesonide-Formoterol Reliever Therapy in Asthma

Thorax
PulmonaryRespiratory Medicine
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy